AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21671102 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited practice session
Number of subjects: 0
Study 21671102 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged practice session
Number of subjects: 0
Study 21671102 — intervention group
Group type: EXPERIMENTAL
Intervention: Single practice session
Number of subjects: 0
Study 21671102 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple practice sessions
Number of subjects: 0
Study 20394251 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia using bupivacaine plus fentanyl
Number of subjects: 30
Study 20394251 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA remifentanil 0.5 microg/kg as a loading bolus, 0.25 microg/kg PCA bolus, continuous infusion of 0.05 microg/kg/min
Number of subjects: 30
Study 17611205 — intervention group
Group type: EXPERIMENTAL
Intervention: Barometric pressures at 8000 ft
Number of subjects: 502
Study 17611205 — intervention group
Group type: EXPERIMENTAL
Intervention: Barometric pressures at 7000 to 8000 ft
Number of subjects: 502
Study 17611205 — intervention group
Group type: COMPARATOR
Intervention: Barometric pressures at all altitudes
Number of subjects: 502
Study 17611205 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure duration of 3 to 9 hours
Number of subjects: 502
Study 17611205 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants older than 60 years
Number of subjects: 502
Study 17611205 — intervention group
Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 502
Study 17611205 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious adverse events
Number of subjects: 502
Study 17611205 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events related to study exposures
Number of subjects: 502
Study 15721762 — intervention group
Group type: EXPERIMENTAL
Intervention: O2‐SPECT
Number of subjects: 26
Study 12147804 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin (20 mg/day p.o.)
Number of subjects: 22
Study 12147804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 10218753 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician nutrition counseling training plus an office-support program (Group 3)
Number of subjects: 1162
Study 10218753 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Group 1)
Number of subjects: 1162
Study 7619749 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (120 mg/sqm day 1) + etoposide (100 mg/sqm days 1-3) every 3 weeks (PE)
Number of subjects: 393
Study 7619749 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (120 mg/sqm every 4 weeks) + mitomycin-C (8 mg/sqm days 1-29-71) + vindesine (3 mg/sqm days 1-8-15-22) (MVP)
Number of subjects: 393
Study 7619749 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (120 mg/sqm day 1) + mitomycin-C (6 mg/sqm day 1) + ifosfamide (3 mg/sqm day 2) every 3 weeks (MIC)
Number of subjects: 393
Study 2797631 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of aspirin per day
Number of subjects: 40
Study 2797631 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg of aspirin per day
Number of subjects: 40
Study 2797631 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg of aspirin per day
Number of subjects: 40
Study 2797631 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 402800 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 141
Study 402800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study 31729443 — intervention group
Group type: EXPERIMENTAL
Intervention: Biophysical propensity scales as input features for ML methods
Number of subjects: 0
Study 31729443 — intervention group
Group type: EXPERIMENTAL
Intervention: One-hot encoding
Number of subjects: 0
Study 31729443 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-linear ML methods
Number of subjects: 0
Study 31729443 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning problem-specific embeddings
Number of subjects: 0
Study 29076670 — intervention group
Group type: EXPERIMENTAL
Intervention: Nigella sativa 1g twice a day for 12 weeks
Number of subjects: 70
Study 26063318 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenzhu Guanxin Recipe (SGR)
Number of subjects: 187
Study 26063318 — intervention group
Group type: COMPARATOR
Intervention: Standard Western Medicine Treatment (SWMT)
Number of subjects: 187
Study 23952636 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirasemtiv (375 mg daily for two weeks, with and without riluzole; 500 mg daily in two divided doses for three weeks)
Number of subjects: 0
Study 23952636 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirasemtiv
Number of subjects: 0
Study 21730078 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped collaborative care intervention
Number of subjects: 0
Study 21730078 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 0
Study 19197573 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal mineral water treatment
Number of subjects: 71
Study 19197573 — intervention group
Group type: COMPARATOR
Intervention: Tap water treatment (Control)
Number of subjects: 71
Study 17378201 — intervention group
Group type: EXPERIMENTAL
Intervention: Lianquan (RN 23) and para-Lianquan deep multi-needling (group B)
Number of subjects: 111
Study 17378201 — intervention group
Group type: COMPARATOR
Intervention: Single Lianquan RN 23 shallow needling (group A1)
Number of subjects: 111
Study 17378201 — intervention group
Group type: COMPARATOR
Intervention: Single Lianquan (RN 23) deep needling (group A2)
Number of subjects: 111
Study 15505457 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine infusion (90 seconds)
Number of subjects: 8
Study 15505457 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion (90 seconds)
Number of subjects: 8
Study 11678162 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol GS (TIMOPTIC‐XE), 0.5% once daily
Number of subjects: 6
Study 11678162 — intervention group
Group type: COMPARATOR
Intervention: Timolol maleate ophthalmic solution, 0.5% twice daily
Number of subjects: 6
Study 9142351 — intervention group
Group type: EXPERIMENTAL
Intervention: Two models of brief family education
Number of subjects: 0
Study 9142351 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 0
Study 7706505 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization (EMD)
Number of subjects: 36
Study 7706505 — intervention group
Group type: COMPARATOR
Intervention: Imaginal Exposure (Image Habituation Training - IHT)
Number of subjects: 36
Study 7706505 — intervention group
Group type: COMPARATOR
Intervention: Applied Muscle Relaxation (AMR)
Number of subjects: 36
Study 3311549 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 20
Study 3311549 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 20
Study 3311549 — intervention group
Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 20
Study 3311549 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine and Nicardipine
Number of subjects: 20
Study 29298456 — intervention group
Group type: EXPERIMENTAL
Intervention: 17‐OHPC
Number of subjects: 21
Study 29298456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 26853333 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical staging followed by chemoradiation therapy (CRT) (arm A)
Number of subjects: 240
Study 26853333 — intervention group
Group type: COMPARATOR
Intervention: Clinical staging followed by chemoradiation therapy (CRT) (arm B)
Number of subjects: 240
Study 26853333 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity modulated radiation therapy (IMRT)
Number of subjects: 240
Study 26853333 — intervention group
Group type: COMPARATOR
Intervention: 3-dimensional technique
Number of subjects: 240
Study 26853333 — intervention group
Group type: EXPERIMENTAL
Intervention: IMRT
Number of subjects: 240
Study 26178889 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronate (5 mg intravenously per year for two years)
Number of subjects: 110
Study 26178889 — intervention group
Group type: COMPARATOR
Intervention: Control (no zoledronate)
Number of subjects: 110
Study 22396248 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle maintenance programme (n = 112)
Number of subjects: 210
Study 22396248 — intervention group
Group type: COMPARATOR
Intervention: Standard care (n = 98)
Number of subjects: 210
Study 21907496 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet program for smoking cessation (6 months duration, with 1 to 7 individual counseling sessions)
Number of subjects: 477
Study 21907496 — intervention group
Group type: COMPARATOR
Intervention: Assessment only control group
Number of subjects: 477
Study 18179480 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention consisting of twelve individual sessions (9 home sessions and 3 telephone sessions) and five telephone support-group sessions.
Number of subjects: 112
Study 18179480 — intervention group
Group type: COMPARATOR
Intervention: Control group received two 'check in' phone calls.
Number of subjects: 112
Study 16731539 — intervention group
Group type: EXPERIMENTAL
Intervention: TAM‐LHRHa (LHRH agonist plus tamoxifen)
Number of subjects: 333
Study 16731539 — intervention group
Group type: COMPARATOR
Intervention: FEC50 (fluorouracil, epirubicin, cyclophosphamide)
Number of subjects: 333
Study 15382712 — intervention group
Group type: EXPERIMENTAL
Intervention: Group counseling with visual aids
Number of subjects: 1054
Study 15382712 — intervention group
Group type: COMPARATOR
Intervention: Group counseling without visual aids
Number of subjects: 1054
Study 11270525 — intervention group
Group type: EXPERIMENTAL
Intervention: Color Doppler ultrasonography (Group B)
Number of subjects: 124
Study 11270525 — intervention group
Group type: COMPARATOR
Intervention: Physical examination only (Group A)
Number of subjects: 124
Study 9037322 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension (systolic and diastolic)
Number of subjects: 950
Study 8143951 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g of alcohol
Number of subjects: 16
Study 8143951 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 16
Study 8143951 — intervention group
Group type: COMPARATOR
Intervention: Lundh test meal with water
Number of subjects: 16
Study 3548626 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ketoconazole, 400 mg/d
Number of subjects: 56
Study 3548626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 31549147 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month treatment regimen containing clofazimine (CFZ)
Number of subjects: 135
Study 31549147 — intervention group
Group type: COMPARATOR
Intervention: 18-month treatment regimen (control group)
Number of subjects: 135
Study 31549147 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 135
Study 28902669 — intervention group
Group type: EXPERIMENTAL
Intervention: ALPPS
Number of subjects: 97
Study 28902669 — intervention group
Group type: COMPARATOR
Intervention: TSH
Number of subjects: 97
Study 27423382 — intervention group
Group type: EXPERIMENTAL
Intervention: MMRV+MenC
Number of subjects: 716
Study 27423382 — intervention group
Group type: COMPARATOR
Intervention: MMRV
Number of subjects: 716
Study 27423382 — intervention group
Group type: COMPARATOR
Intervention: MenC
Number of subjects: 716
Study 23183371 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral component implanted in 4° flexion (F)
Number of subjects: 39
Study 23183371 — intervention group
Group type: COMPARATOR
Intervention: Femoral component implanted in a neutral position (C)
Number of subjects: 39
Study 22513429 — intervention group
Group type: EXPERIMENTAL
Intervention: High-tie vascular transections
Number of subjects: 30
Study 22513429 — intervention group
Group type: COMPARATOR
Intervention: Low-tie vascular transections
Number of subjects: 30
Study 22513429 — intervention group
Group type: EXPERIMENTAL
Intervention: High-tie vascular transections after secondary left colic artery division
Number of subjects: 30
Study 21171261 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin 0.2 mg qd
Number of subjects: 184
Study 21171261 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of tamsulosin and tolterodine 2 mg bid
Number of subjects: 184
Study 18487001 — intervention group
Group type: COMPARATOR
Intervention: Passive Cycling Movements (PCMs)
Number of subjects: 10
Study 18487001 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous Electrical Muscle Stimulation (TEMS)
Number of subjects: 10
Study 18487001 — intervention group
Group type: EXPERIMENTAL
Intervention: No Intervention (NI)
Number of subjects: 10
Study 16162055 — intervention group
Group type: EXPERIMENTAL
Intervention: White Identity Centrality Implicit Association Test (WICIAT)
Number of subjects: 0
Study 12593316 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentle human touch nursing intervention
Number of subjects: 0
Study 10499246 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmastectomy locoregional radiation therapy
Number of subjects: 0
Study 7798683 — intervention group
Group type: COMPARATOR
Intervention: Active postexposure prophylaxis with two different vaccines
Number of subjects: 166
Study 7798683 — intervention group
Group type: EXPERIMENTAL
Intervention: Active postexposure prophylaxis
Number of subjects: 166
Study 7798683 — intervention group
Group type: COMPARATOR
Intervention: Passive-active immunoprophylaxis with high-dose hepatitis B immune globulin
Number of subjects: 166
Study 2687639 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss program
Number of subjects: 77
Study 2687639 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training program
Number of subjects: 77
Study 2687639 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 77
Study 30959314 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin treatment (14-day duration)
Number of subjects: 3977
Study 30959314 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 3977
Study 30959314 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (clarithromycin and placebo)
Number of subjects: 3977
Study 27730425 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab (IVR) injections and short pulse focal/grid laser photocoagulation
Number of subjects: 21
Study 26176347 — intervention group
Group type: EXPERIMENTAL
Intervention: N(G)‐monomethyl‐L‐arginine (L‐NMMA)
Number of subjects: 26
Study 26176347 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (pre-treatment)
Number of subjects: 26
Study 26176347 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (pre-treatment)
Number of subjects: 26
Study 26176347 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐NMMA
Number of subjects: 26
Study 22762238 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of neuromuscular electrical stimulation (NMES) and balloon dilatation for 4 months
Number of subjects: 60
Study 22762238 — intervention group
Group type: COMPARATOR
Intervention: Routine rehabilitation treatment
Number of subjects: 60
Study 22762238 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of NMES and balloon dilatation
Number of subjects: 60
Study 21404198 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubeless PCNL (group A)
Number of subjects: 200
Study 21404198 — intervention group
Group type: COMPARATOR
Intervention: Nephrostomy tube in place (group B)
Number of subjects: 200
Study 19634161 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly carboplatin (AUC 1.5) and paclitaxel (45 mg/m2) with daily subcutaneous amifostine (500 mg)
Number of subjects: 58
Study 19634161 — intervention group
Group type: COMPARATOR
Intervention: Weekly carboplatin (AUC 1.5) and paclitaxel (45 mg/m2) without amifostine
Number of subjects: 58
Study 19634161 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly carboplatin/paclitaxel with concomitant boost radiation
Number of subjects: 58
Study 19634161 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly carboplatin/paclitaxel with daily subcutaneous amifostine
Number of subjects: 58
Study 17526165 — intervention group
Group type: EXPERIMENTAL
Intervention: Spleen-invigorating Prescription (SIP), orally, twice a day for 6 months
Number of subjects: 60
Study 17526165 — intervention group
Group type: COMPARATOR
Intervention: Control group: intramuscular injection with human interferon alpha 1b, 3 times a week
Number of subjects: 60
Study 15063521 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity pulsed ultrasound (LIPUS), 20 min/day for 90 days
Number of subjects: 30
Study 15063521 — intervention group
Group type: COMPARATOR
Intervention: Dummy machine (sham-exposed)
Number of subjects: 30
Study 15063521 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity pulsed ultrasound (LIPUS) for delayed union treatment
Number of subjects: 30
Study 11511482 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-at-home schemes
Number of subjects: 0
Study 11511482 — intervention group
Group type: COMPARATOR
Intervention: Standard hospital care
Number of subjects: 0
Study 9750575 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult day care use
Number of subjects: 0
Study 9750575 — intervention group
Group type: COMPARATOR
Intervention: Control group (no adult day care use)
Number of subjects: 0
Study 7908268 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroid (budesonide) plus beta 2-agonist (salbutamol) 0.2 mg, t.i.d.
Number of subjects: 58
Study 7908268 — intervention group
Group type: COMPARATOR
Intervention: Beta 2-agonist (salbutamol) alone
Number of subjects: 58
Study 3465425 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (gamma-vinyl GABA) at a daily dose of 2-4 g for 4 months
Number of subjects: 14
Study 3465425 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (gamma-vinyl GABA) at a daily dose of 2 g/day for 3 months
Number of subjects: 14
Study 3465425 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (gamma-vinyl GABA) at a daily dose of 4 g/day
Number of subjects: 14
Study 3465425 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (gamma-vinyl GABA) at a daily dose of 2 g/day
Number of subjects: 14
Study 3465425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 30567490 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone (0.2 mg/kg) + dezocine (0.5 mg/kg) + ramosetron (0.6 mg) diluted with normal saline to 200 mL
Number of subjects: 142
Study 30567490 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil (3.0 μg/kg) + dezocine (0.5 mg/kg) + ramosetron (0.6 mg) diluted with normal saline to 200 mL
Number of subjects: 142
Study 26551550 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramosetron 2.5 μg once daily for 12 weeks
Number of subjects: 576
Study 26551550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 576
Study 23575360 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-myofascial release (SMR) using a foam roller
Number of subjects: 10
Study 23575360 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 10
Study 23071202 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine supplementation in the first month after birth
Number of subjects: 52
Study 23071202 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine group
Number of subjects: 52
Study 23071202 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine supplementation
Number of subjects: 52
Study 20033720 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichaotic music (auditory stress)
Number of subjects: 8
Study 20033720 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical music (auditory relaxation)
Number of subjects: 8
Study 20033720 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental loading (mental arithmetic tasks)
Number of subjects: 8
Study 20033720 — intervention group
Group type: COMPARATOR
Intervention: Silence
Number of subjects: 8
Study 18714795 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagus Nerve Stimulator (VNS)
Number of subjects: 35
Study 18714795 — intervention group
Group type: COMPARATOR
Intervention: Cerebral resective surgery
Number of subjects: 35
Study 18714795 — intervention group
Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 35
Study 18626707 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release oxycodone administered 1 hour before surgery and 12 hours after the first administration
Number of subjects: 50
Study 18626707 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release oxycodone
Number of subjects: 50
Study 18626707 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered at the same intervals as oxycodone
Number of subjects: 50
Study 15447698 — intervention group
Group type: EXPERIMENTAL
Intervention: Rizatriptan 5 mg (tablets)
Number of subjects: 234
Study 15447698 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study 15447698 — intervention group
Group type: EXPERIMENTAL
Intervention: Rizatriptan 5 mg (wafers)
Number of subjects: 234
Study 15447698 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 234
Study 11228217 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.75 mg triptorelin (conventional dose)
Number of subjects: 60
Study 11228217 — intervention group
Group type: COMPARATOR
Intervention: 1.87 mg triptorelin (low dose)
Number of subjects: 60
Study 11228217 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses of triptorelin
Number of subjects: 60
Study 9288279 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous nerve stimulation (TNS)
Number of subjects: 26
Study 9288279 — intervention group
Group type: COMPARATOR
Intervention: Nontreated controls
Number of subjects: 26
Study 8491403 — intervention group
Group type: EXPERIMENTAL
Intervention: Food discussion
Number of subjects: 5
Study 8491403 — intervention group
Group type: EXPERIMENTAL
Intervention: Smell of food without sight or taste
Number of subjects: 5
Study 8491403 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham feeding
Number of subjects: 5
Study 8491403 — intervention group
Group type: EXPERIMENTAL
Intervention: Sight and smell of food without taste
Number of subjects: 5
Study 8491403 — intervention group
Group type: EXPERIMENTAL
Intervention: Sight of food without smell or taste
Number of subjects: 5
Study 8491403 — intervention group
Group type: COMPARATOR
Intervention: Control stimulus (discussion of neutral topics)
Number of subjects: 5